<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA061389-0080</title>
	</head>
	<body>
		<main>
			<p><P> June 13, 1989, Tuesday, Valley Edition  </P> <P> VALLEY ROUNDUP: AMGEN PREPARING OFFERING OF DEBENTURES OVERSEAS  </P> <P> Amgen said it has started preparing for a $50-million offering of subordinated  convertible debentures to investors overseas, mainly in Europe.  </P> <P> A convertible debenture is an unsecured bond that ultimately may be exchanged  for stock in a company. Amgen, a Thousand Oaks biotechnology company, is being  assisted in preparing the offering by Morgan Stanley International.  </P> <P> Earlier this month, the U.S. Food and Drug Administration approved the sale of  Amgen's biotechnology drug erythropoietin, a long-awaited protein that treats  chronic anemia in patients with kidney disease.  </P></p>
		</main>
</body></html>
            